Maternal care for anti-D [Rh] antibodies, third trimester (fetus 2)
ICD-10 O36.0132 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, third trimester (fetus 2).
O36.0132 refers to maternal care for a pregnant woman who has developed anti-D (Rh) antibodies during the third trimester of pregnancy, specifically concerning the second fetus in a multiple gestation. This condition arises when an Rh-negative mother is exposed to Rh-positive fetal blood, leading to the production of antibodies that can cross the placenta and potentially harm the fetus. The clinical implications include risks of hemolytic disease of the newborn (HDN), fetal growth restriction, and fetal distress. Monitoring and management strategies may involve regular ultrasound assessments to evaluate fetal growth and well-being, as well as possible interventions such as intrauterine transfusions if severe anemia is detected. Maternal care must be comprehensive, including education on the condition, potential complications, and the importance of follow-up care to ensure both maternal and fetal health.
Documentation must include maternal blood type, antibody screening results, and detailed fetal monitoring records.
Management of a pregnant woman with known Rh sensitization, monitoring for fetal growth restriction, and addressing fetal distress.
Accurate coding requires understanding of maternal-fetal medicine principles and the implications of Rh incompatibility.
High-risk pregnancy documentation must include detailed ultrasound findings, maternal health status, and any interventions performed.
Complex cases involving intrauterine transfusions or close monitoring of fetal well-being due to Rh sensitization.
Considerations for high-risk obstetric coding include the need for specialized care plans and interdisciplinary communication.
Used for routine monitoring of fetal growth and well-being in cases of Rh sensitization.
Documentation must include indications for the ultrasound and findings related to fetal growth.
Obstetricians should ensure that ultrasound findings are clearly linked to the diagnosis of anti-D antibodies.
Accurate coding of O36.0132 is crucial for ensuring appropriate maternal and fetal care, as it reflects the complexity of managing Rh sensitization and its potential complications. Proper coding also impacts reimbursement and quality of care metrics.
